Olea Venture Partners Managing Partner Harietta Eleftherochorinou moderated a discussion on what it takes to build the next generation of AI companies in life sciences.
Bringing together perspectives from entrepreneurship, pharma, technology and investment, the conversation explored how AI-native companies can build lasting differentiation, scale within complex healthcare environments, create successful partnerships with large pharma, and turn strong technology into enduring enterprise value.
The panel featured Huafeng Xu, Founder and CEO of Fathom Therapeutics; Yannis Pandis, Site Lead and Leader of the Centre for Digital Innovation at Pfizer; Evangelia Loizou, Senior Engagement Lead at Intelligencia AI; and Dimitris Agrafiotis, Director at Arsenal Capital Partners.
The discussion was grounded in a common question: as AI lowers the barriers to building new companies, what distinguishes those that create lasting impact in healthcare and life sciences?